The Journal of Heart and Lung Transplantation
Volume 29, Issue 4 , Pages 389-394 , April 2010

Controversies in defining cardiac antibody-mediated rejection: Need for updated criteria

  • Abdallah G. Kfoury, MD

      Affiliations

    • Intermountain Medical Center and Intermountain Healthcare, Cardiac Transplant Program, Salt Lake City, Utah
    • Utah Transplantation Affiliated Hospitals (U.T.A.H.) Cardiac Transplant Program, Salt Lake City, Utah
    • Corresponding Author InformationReprint requests: Abdallah G. Kfoury, MD, Heart Failure Prevention and Treatment Program, Intermountain Medical Center, 5121 South Cottonwood Street, Salt Lake City, UT 84107. Telephone: 801-507-4637. Fax: 801-507-4811
    • ,
  • M. Elizabeth H. Hammond, MD

      Affiliations

    • Intermountain Medical Center and Intermountain Healthcare, Cardiac Transplant Program, Salt Lake City, Utah
    • Utah Transplantation Affiliated Hospitals (U.T.A.H.) Cardiac Transplant Program, Salt Lake City, Utah

References 

  1. Hammond MEH, Yowell RL, Nunoda S, et al. Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications. J Heart Lung Transplant. 1989;8:430–443
  2. Taylor DO, Yowell RL, Kfoury AG, et al. Allograft coronary artery disease: clinical correlations with circulating anti-HLA antibodies and the immunohistopathologic pattern of vascular rejection. J Heart Lung Transplant. 2000;518–521
  3. Michaels PJ, Espejo ML, Kobashigawa J, et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant. 2003;22:58–69
  4. Lones MA, Czer LS, Trento A, et al. Clinical–pathologic features of humoral rejection in cardiac allografts: a study in 81 consecutive patients. J Heart Lung Transplant. 1995;14:151–162
  5. Labarrere CA, Nelson DR, Faulk WP. Endothelial activation and development of coronary artery disease in transplanted human hearts. JAMA. 1997;278:1169–1175
  6. Ratliff NB, McMahon JT. Activation of intravascular macrophages within myocardial small vessels is a feature of acute vascular rejection in human heart transplants. J Heart Lung Transplant. 1995;14:338–345
  7. Hallgren R, Gerdin B, Tengblad A, et al. Accumulation of hyaluronan (hyaluronic acid) in myocardial interstitial tissue parallels development of transplantation edema in heart allografts in rats. J Clin Invest. 1990;85:668–673
  8. Hammond EH, Hansen JK, Spencer LS, et al. Vascular rejection in cardiac transplantation: histologic, immunopathologic, and ultrastructural features. Cardiovasc Pathol. 1993;2:21–34
  9. Petrossian GA, Nichols AB, Marboe CC, et al. Relation between survival and development of coronary artery disease and anti-HLA antibodies after cardiac transplantation. Circulation. 1989;80:III-122-5
  10. Reed EF, Hong B, Ho E, et al. Monitoring of soluble HLA alloantigens and anti-HLA antibodies identifies heart allograft recipients at risk of transplant-associated coronary artery disease. Transplantation. 1996;61:566–572
  11. Rose ML. Role of antibodies in rejection. Curr Opin Organ Transplant. 1999;4:227–233
  12. McKenna RM, Takemoto SK, Terasaki PI. Anti-HLA antibodies after solid organ transplantation. Transplantation. 2000;69:319–326
  13. Stewart S, Winters G, Fishbein M, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant. 2005;24:1710–1720
  14. Reed E, Demetris A, Hammond ME, et al. Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant. 2006;25:153–159
  15. Billingham ME, Cary NRB, Hammond EH, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection. J Heart Transplant. 1990;9:587–593
  16. Mölne J, Breimer ME, Svalander CT. Immunoperoxidase versus immunofluorescence in the assessment of human renal biopsies. Am J Kidney Dis. 2005;45:674–683
  17. Howie AJ, Gregory J, Thompson RA, et al. Technical improvements in the immunoperoxidase study of renal biopsy specimens. J Clin Pathol. 1990;43:257–259
  18. Chantranuat C, Qiao JH, Kobashigawa J, et al. Immunoperoxidase staining for C4d on paraffin-embedded tissue in cardiac allograft endomyocardial biopsies: comparison to frozen tissue immunofluorescence. Appl Immunhistochem Mol Morphol. 2004;12:166–171
  19. Ludovico-Martins H, Silva C, Teodoro WR, et al. Analysis of different staining techniques for C4d detection in renal allograft biopsies. Transplant Proc. 2009;41:862–865
  20. Seemayer CA, Gaspert A, Nickeleit V, et al. C4d staining of renal allograft biopsies: a comparative analysis of different staining techniques. Nephrol Dial Transplant. 2007;22:568–576
  21. Ludvico-Martins H, Silva C, Teodoro WR, et al. Analysis of different staining techniques for C4d detection in renal allograft biopsies. Transplant Proc. 2009;41:862–865
  22. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008;8:753–760
  23. Smith RN, Kawai T, Boskovic S, et al. Four stages and lack of stable accommodation in chronic alloantibody-mediated allograft rejection in Cynomolgus monkeys. Am J Transplant. 2008;8:1662–1672
  24. Shimizu A, Hisashi Y, Kuwaki K, et al. Thrombotic microangiopathy associated with humoral rejection of cardiac xenografts from alpha1,3-galactosyltransferase gene-knockout pigs in baboons. Am J Pathol. 2008;172:1471–1481
  25. Murata K, Fox-Talbot K, Qian Z, et al. Synergistic deposition of C4d by complement-activating and non-activating antibodies in cardiac transplants. Am J Transplant. 2007;7:2605–2614
  26. Batal I, Girnita A, Zeevi A, et al. Clinical significance of the distribution of C4d deposits in different anatomic compartments of the allograft kidney. Mod Pathol. 2008;21:1490–1498
  27. Behr TM, Feucht HE, Richter K, et al. Detection of humoral rejection in human cardiac allografts by assessing the capillary deposition of complement fragment C4d in endomyocardial biopsies. J Heart Lung Transplant. 1999;18:904–912
  28. Rodriguez ER, Skojec DV, Tan CD, et al. Antibody-mediated rejection in human cardiac allografts: evaluation of immunoglobulins and complement activation products C4d and C3d as markers. Am J Transplant. 2005;5:2778–2785
  29. Murata K, Baldwin WM. Mechanisms of complement activation, C4d deposition, and their contribution to the pathogenesis of antibody-mediated rejection. Transplant Rev (Orlando). 2009;23:139–150
  30. Tan CD, Sokos GG, Pidwell DJ, et al. Correlation of donor-specific antibodies, complement and its regulators with graft dysfunction in cardiac antibody-mediated rejection. Am J Transplant. 2009;9:2075–2084
  31. Baldwin WM, Samaniego-Picota M, Kasper EK, et al. Complement deposition in early cardiac transplant biopsies is associated with ischemic injury and subsequent rejection episodes. Transplantation. 1999;68:894–900
  32. Spiller OB, Morgan BP. Antibody-independent activation of the classical complement pathway by cytomegalovirus-infected fibroblasts. J Infect Dis. 1998;178:1597–1603
  33. Van Strijp JA, Van Kessel KP, Miltenburg LA, et al. Attachment of human polymorphonuclear leukocytes to herpes simplex virus-infected fibroblasts mediated by antibodies-independent complement activation. J Virol. 1988;62:847–850
  34. Vallhonrat H, Williams WW, Cosimi AB, et al. In vivo generation of C4d, Bb, iC3b, and SC5b-9 after OKT3 administration in kidney and lung transplant recipients. Transplantation. 1999;67:253–258
  35. Martin S, Brenchley PE, O'Donoghue DJ, et al. The identification of allo- and auto-lymphocytotoxic antibodies in serum, in the presence of rabbit antithymocyte globulin. Tissue Antigens. 1988;31:26–32
  36. Manyak CL, Tse H, Fischer P, et al. Regulation of class II MHC molecules on human endothelial cells (Effects of IFN and dexamethasone). J Immunol. 1988;140:3817–3821
  37. McDouall RM, Batten P, McCormack A, et al. MHC class II expression on human heart microvascular endothelial cells: exquisite sensitivity to interferon-gamma and natural killer cells. Transplantation. 1997;64:1175–1180
  38. Labarrere CA, Torry RJ, Nelson DR, et al. Vascular antithrombin and clinical outcome in heart transplant patients. Am J Cardiol. 2001;87:425–431
  39. Shimizu A, Colvin RB. Pathological features of antibody-mediated rejection (Pathological features of antibody-mediated rejection). Curr Drug Targets Cardiovasc Haematol Disord. 2005;5:199–214
  40. Meehan SM, Limsrichamren S, Manaligod JR, et al. Platelets and capillary injury in acute humoral rejection of renal allografts. Hum Pathol. 2003;34:533–540
  41. Kirk AD, Morrell CN, Baldwin WM. Platelets influence vascularized organ transplants from start to finish. Am J Transplant. 2009;9:14–22
  42. Tay SS, McCormack A, Rose ML. Effect of cognate human CD4+ T cell and endothelial cell interactions upon chemokine production. Transplantation. 2004;78:987–994
  43. Kedainis RL, Koch MJ, Brennan DC, et al. Focal C4d+ in renal allografts is associated with the presence of donor-specific antibodies and decreased allograft survival. Am J Transplant. 2009;9:812–819
  44. Nwakanma LU, Williams JA, Weiss ES, et al. Influence of pretransplant panel-reactive antibody on outcomes in 8,160 heart transplant recipients in recent era. Ann Thorac Surg. 2007;84:1556–1562
  45. Jurcevic S, Ainsworth ME, Pomerance A, et al. Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation. 2001;71:886–892
  46. Fredrich R, Toyoda M, Czer LS, et al. The clinical significance of antibodies to human vascular endothelial cells after cardiac transplantation. Transplantation. 1999;67:385–391
  47. Kobashigawa J, Mehra M, West L, et al. Report form a consensus conference on the sensitized patient awaiting heart transplantation. J Heart Lung Transplant. 2009;28:213–225
  48. Michaels PJ, Fishbein MC, Colvin RB. Humoral rejection of human organ transplants. Springer Semin Immunopathol. 2003;25:119–140
  49. Kfoury AG, Hammond EH, Snow GL, et al. Early screening for antibody-mediated rejection in heart transplant recipients. J Heart Lung Transplant. 2007;26:1264–1269
  50. Almuti K, Haythe J, Dwyer E, et al. The changing pattern of humoral rejection in cardiac transplant recipients. Transplantation. 2007;84:498–503
  51. Fishbein MC, Kobashigawa J. Biopsy-negative cardiac transplant rejection: etiology, diagnosis, and therapy. Curr Opin Cardiol. 2004;19:166–169
  52. Hammond ME, Stehlik J, Snow G, et al. Utility of histologic parameters in screening for antibody-mediated rejection of the cardiac allograft: a study of 3,170 biopsies. J Heart Lung Transplant. 2005;24:2015–2021
  53. Hammond MEH, Renlund DG. Cardiac allograft vascular (microvascular) rejection. Curr Opin Organ Transplant. 2002;7:233–239
  54. Mueller A, Schnuelle P, Waldherr R, et al. Impact of the Banff'97 classification for histological diagnosis of rejection on clinical outcome and renal function parameters after kidney transplantation. Transplantation. 2000;69:1123–1127
  55. Mauiyyedi S, Crespo M, Collins AB, et al. Acute humoral rejection in kidney transplantation: II (Morphology, immunopathology, and pathologic classification). J Am Soc Nephrol. 2002;13:779–787
  56. Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant. 2004;4:1033–1041
  57. Kfoury AG, Stehlik J, Renlund DG, et al. Impact of repetitive episodes of antibody-mediated or cellular rejection on cardiovascular mortality in cardiac transplant recipients: defining rejection patterns. J Heart Lung Transplant. 2006;25:1277–1282
  58. Wu GW, Kobashigawa JA, Fishbein MC, et al. Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes. J Heart Lung Transplant. 2009;28:417–422
  59. Kfoury AG, Hammond ME, Snow GL, et al. Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody-mediated rejection. J Heart Lung Transplant. 2009;28:781–784
  60. Kfoury AG, Renlund DG, Snow GL, et al. A clinical correlation study of severity of antibody-mediated rejection and cardiovascular mortality in heart transplantation. J Heart Lung Transplant. 2009;28:51–57

PII: S1053-2498(09)00849-3

doi: 10.1016/j.healun.2009.10.016

The Journal of Heart and Lung Transplantation
Volume 29, Issue 4 , Pages 389-394 , April 2010

Article Tools

* Image Usage & Resolution